MDGL

MDGL

USD

Madrigal Pharmaceuticals Inc. Common Stock

$489.260+1.230 (0.252%)

Echtzeitkurs

Healthcare
Biotechnologie
Vereinigte Staaten

Kursdiagramm

Loading Chart...

Schlüsselkennzahlen

Marktkennzahlen
Unternehmensfundamentaldaten
Handelsstatistiken

Marktkennzahlen

Eröffnung

$488.030

Hoch

$494.550

Tief

$477.000

Volumen

0.76M

Unternehmensfundamentaldaten

Marktkapitalisierung

11.1B

Branche

Biotechnologie

Land

United States

Handelsstatistiken

Durchschnittliches Volumen

0.37M

Börse

NMS

Währung

USD

52-Wochen-Spanne

Tief $265Aktuell $489.260Hoch $496.98

Ähnliche Nachrichten

Analyst Upgrades

B of A Securities Upgrades Madrigal Pharmaceuticals to Neutral, Raises Price Target to $445

B of A Securities analyst Alexandria Hammond upgrades Madrigal Pharmaceuticals from Underperform to Neutral and raises the price target from $266 to $445.

Mehr anzeigen
B of A Securities Upgrades Madrigal Pharmaceuticals to Neutral, Raises Price Target to $445
GlobeNewswire

Madrigal to Present New Data from the Company's MASH Program at AASLD's The Liver Meeting 2025

Two oral presentations to highlight biomarker, imaging and quality-of-life data from the open-label compensated MASH cirrhosis (F4c) arm of the Phase 3 MAESTRO-NAFLD-1 trial of RezdiffraPoster of distinction examines the

Mehr anzeigen
Madrigal to Present New Data from the Company's MASH Program at AASLD's The Liver Meeting 2025
GlobeNewswire

Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)

CONSHOHOCKEN, Pa., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated

Mehr anzeigen
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
Analyst Upgrades

Truist Securities Initiates Coverage On Madrigal Pharmaceuticals with Buy Rating, Announces Price Target of $580

Truist Securities analyst Srikripa Devarakonda initiates coverage on Madrigal Pharmaceuticals with a Buy rating and announces Price Target of $580.

Mehr anzeigen
Truist Securities Initiates Coverage On Madrigal Pharmaceuticals with Buy Rating, Announces Price Target of $580

Bleiben Sie auf dem Laufenden

Preisalarme setzen, KI-Analyse-Updates und Echtzeit-Marktnachrichten erhalten.